Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non-small cell lung cancer and mutated EGFR.

Alejandro Vila PérezEmilio J Alegre-Del ReySilvia Fénix-CaballeroZuzana ŠpacírováPetra Rosado VarelaAntonio Olry de Labry Lima

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)

Taking into account a Spanish threshold of 24,000 €/QALY, the reduction in the acquisition cost of osimertinib will have to be greater than 10%, to obtain a cost-effective alternative.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
early stage
advanced non small cell lung cancer
tyrosine kinase
wild type